Company news

Insmed Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

June 10, 2025

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

June 9, 2025

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

May 27, 2025

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

May 20, 2025

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

May 7, 2025

Insmed To Present at the BofA Securities 2025 Health Care Conference

April 28, 2025

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

April 23, 2025

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

April 22, 2025

Insmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

April 22, 2025

Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

March 24, 2025

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

February 23, 2025

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

February 19, 2025

Insmed To Present at March 2025 Investor Conferences

February 10, 2025

Insmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

February 9, 2025

FDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

February 5, 2025

Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

Insmed To Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 1, 2025

Insmed To Present at December 2024 Investor Conferences

December 1, 2024

Insmed To Present at November 2024 Investor Conferences

November 5, 2024

Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update

October 30, 2024

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

October 23, 2024

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good

October 22, 2024

Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024

October 16, 2024

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

October 7, 2024

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update

August 7, 2024

Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024

July 28, 2024

Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference

July 2, 2024

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025

June 26, 2024

Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Insmed to Host Commercial Webinar on June 4, 2024

May 29, 2024

Insmed Announces Pricing of $650 Million Public Offering of Common Stock

May 29, 2024

Insmed Announces Proposed $500 Million Public Offering of Common Stock

May 27, 2024

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis

May 27, 2024

Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

May 26, 2024

Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International C...

May 19, 2024

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update

May 8, 2024

Insmed To Present at the BofA Securities Health Care Conference 2024

May 6, 2024

Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024

April 24, 2024

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

March 26, 2024

Insmed To Present at Three March Conferences

February 28, 2024

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health

February 27, 2024

Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update

February 21, 2024

Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024

February 7, 2024

Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference

January 4, 2024

Insmed To Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 1, 2024

Insmed To Present at the Nasdaq 49th Investor Conference

November 28, 2023

Insmed To Present at Two November Conferences

November 7, 2023

Insmed Holds Second Annual Global Day of Good to Benefit Communities Across the Globe

November 1, 2023

Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update

October 25, 2023

Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List

October 25, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 49 decks. Every deck is listed under its year.